RBC Capital Maintains Ligand Pharmaceuticals Incorporated

RBC Capital maintained coverage of Ligand Pharmaceuticals’ equity right (OTCPK:LGNXZ) with an Outperform on Dec. 10, 2025, but Fintel’s aggregated analyst data as of Dec. 6 shows an anomalous average one‑year price target of $0.00, which it reports as a 23.5% downside versus the latest quoted closing price; readers should note the zero price‑target figures likely reflect a data anomaly. Fintel also projects annual revenue of $161 million (down 35.8%) and a non‑GAAP EPS of 3.99, and reports institutional ownership unchanged at five funds holding roughly 425K shares—dominated by Vanguard Extended Market Index Fund with 396K shares—while average portfolio weight is reported at 0.00% (up 32.02%).

Analysis

RBC Capital maintained coverage of Ligand Pharmaceuticals Incorporated - Equity Right (OTCPK:LGNXZ) with an Outperform on December 10, 2025. Fintel's aggregated data as of December 6 reports an average one‑year price target of $0.00 and a latest closing price of $0.00, figures that are internally inconsistent and point to a reporting/data anomaly in the price‑target aggregation.

Fintel projects annual revenue of $161 million, a decline of 35.8%, alongside a projected non‑GAAP EPS of 3.99; if accurate, the revenue contraction implies meaningful near‑term top‑line pressure even as adjusted earnings remain positive. The coexistence of an RBC Outperform and steep reported revenue decline necessitates reviewing the underlying analyst note and company disclosures to reconcile catalysts and assumptions.

Institutional ownership is concentrated in five funds holding roughly 425K shares, with Vanguard Extended Market Index Fund accounting for 396K shares and no reported quarterly changes; average portfolio weight is reported as 0.00% but flagged as up 32.02%, another data inconsistency to verify. Aggregated sentiment is moderately negative (sentiment score −0.5) and per‑ticker sentiment for LGND is −0.6, indicating elevated information risk and potential short‑term valuation volatility until corrected data and primary research are confirmed.

Key Decisions for Investors

• Verify RBC Capital's primary analyst report and company filings before trading given Fintel's $0.00 price‑target and $0.00 close that suggest data errors
• If the reported 35.8% revenue decline to $161M is confirmed, reassess valuation and consider trimming or hedging exposure pending clarity on revenue drivers
• Size any new position conservatively and monitor liquidity given concentration of institutional holdings (Vanguard 396K shares) and unchanged reported positions
• Delay initiating material new positions until aggregate data is corrected and EPS 3.99 and price‑target assumptions are independently confirmed, because sentiment and information risk are elevated